12:15 PM
 | 
Jun 22, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced above its proposed range.

Avrobio raised $99.7 million through the sale of 5.2 million shares at $19. The price valued Avrobio at $439.8 million. The company had planned to sell 4.4 million shares at $16-$18. Underwriters are Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow.

Avrobio is developing a pipeline of CD34+ hematopoietic stem cell therapies that are transduced with lentivirus ex vivo to express therapeutic proteins. This month, Avrobio dosed the first patient in a Phase II...

Read the full 545 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >